75
Participants
Start Date
June 30, 2005
Primary Completion Date
April 30, 2016
Study Completion Date
April 30, 2016
mHSCT
Hematopoietic progenitors were mobilized with G-CSF. After leukapheresis and CD34+ cell enrichment, the autologous product was cryopreserved. Fractionated TBI (800 cGy), CY (120 mg/kg) and equine antithymocyte globulin (90 mg/kg) were administered as previously reported (References provided in citation section of this ClinicalTrials.gov record: PubMed ID: 17452515 citation and 2.) PubMed ID: 12176878 citation).
cyclophosphamide
An initial intravenous dose of 500 mg/m\^2 was followed by 11 infusions of 750 mg/m\^2 with mesna given for bladder protection.
University of Pittsburgh, Pittsburgh
Duke University Medical Center, Durham
Medical University of South Carolina, Charleston
University of Toledo Health Science Campus, Toledo
University of Michigan, Ann Arbor
Medical College of Wisconsin, Milwaukee
Washington University School of Medicine, St Louis
University of Texas-Houston Medical School, Houston
MD Anderson Cancer Center, Houston
Fred Hutchinson Cancer Research Center (FHCRC), Seattle
City of Hope National Medical Center, Duarte
UCLA Medical School, Los Angeles
University of Kentucky, Lexington
Massachusetts General Hospital, Boston
Boston University School of Medicine, Boston
University of Calgary, Calgary
Dr. Markland Medical Professional Corporation, Saskatoon
Rho Federal Systems Division, Inc.
INDUSTRY
National Institute of Allergy and Infectious Diseases (NIAID)
NIH